![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 28, 21140-21148, July 14, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, January 28, 2000, and in revised form, April 5, 2000
Intracellular protein degradation is a major
source of short antigenic peptides that can be presented on the cell
surface in the context of major histocompatibility class I molecules
for recognition by cytotoxic T lymphocytes. The capacity of the most important cytosolic protease, the 20 S proteasome, to generate peptide
fragments with an average length of 7-8 amino acid residues has been
thoroughly investigated. It has been shown that the cleavage products
are not randomly generated, but originate from the commitment of the
catalytically active subunits to complex recognition motifs in the
primary amino acid sequence. The role of the even larger 26 S
proteasome is less well defined, however. It has been demonstrated that
the 26 S proteasome can bind and degrade ubiquitin-tagged proteins and
minigene translation products in vivo and in
vitro, but the nature of the degradation products remains
elusive. In this study, we present the first analysis of cleavage
products from in vitro digestion of the unmodified model
substrate Cells present foreign, altered self, and self antigens to
cytotoxic T lymphocytes
(CTL)1 on the cell surface in
the context of major histocompatibility (MHC) class I molecules.
Following recognition and activation, the CTL then initiate target cell
destruction. The antigenic peptides essential for target cell
recognition are generated in the cytosol by proteolytic degradation of
predominantly endogenous proteins. The resulting pool of peptides is a
possible source for translocation of 7-15-mers by the transporter
associated with antigen processing into the lumen of the endoplasmic
reticulum. Translocated peptides that fulfill the criteria for binding
to the available MHC class I allelic products stabilize membrane-bound,
empty MHC class I heavy chains in association with
Evidence for the significant contribution of the proteasome to the
generation of antigenic peptides in the cytosol has accumulated over
the past decade. Treatment of cells with proteasome inhibitors caused a
significant reduction not only of the in vitro activity of
the proteasome, but also of the surface expression of MHC class I
molecules and the corresponding ligands (4). Furthermore, in many
independent cases, it has been demonstrated that the proteasome is
capable of generating MHC class I restricted CTL epitopes and potential
MHC class I binding peptides from short synthetic precursors in
vivo (5, 6) and in vitro (7). The implication of the 11 S proteasome regulator PA28/20 S proteasome complex in antigen processing (8, 9), as well as the targeted disruption of the loci
coding for the interferon- The 20 S proteasome is a cylindrical particle consisting of 28 subunits
in four stacked, heptameric rings with a C2 axis of symmetry. The two
outer rings comprise The 26 S proteasome is a complex of the 20 S core and either one or two
regulatory particles (14). The RP consists of at least 17 subunits
forming two subcomplexes, the "base" and the "lid" (15, 13).
The RP confers ATP dependence and recognition of polyubiquitinated
protein substrates, leading to substrate unfolding, deubiquitination,
and translocation of the substrate into the 20 S core. It has been
shown that transcription from vectors coding for fusion proteins with
an N-terminal monoubiquitin ligated either to the influenza
nucleoprotein or to a human immunodeficiency virus Nef construct with a
destabilizing arginine in position 1 results in enhanced specific lysis
of transduced target cells. This is in contrast to the lysis of cells
transfected with the same vector without the ubiquitin moiety (16-19).
The rapid turnover of short-lived proteins and the presentation of
resulting fragments on MHC class I molecules depends substantially on
conjugation to ubiquitin, as demonstrated with cell-free as well as
in vivo model systems (20, 21). Some proteins such as casein
(22-24) and chemically modified ovalbumin (25), are degraded via the 26 S pathway without ubiquitin tagging. In the presence of antizyme, recombinant ornithine decarboxylase enharboring the
H2-Kb-restricted CTL epitope SIINFEKL from ovalbumin is a
suitable substrate for the 26 S proteasome. The latter regulates the
production of the intact SIINFEKL epitope and an N-terminally extended
precursor peptide with the correct C terminus (26). These findings
support the assumption that the proteasome is responsible for the
generation of the proper C termini for MHC class I ligands, whereas the
generation of the N terminus is more likely to be the result of MHC
class I-dependent trimming activities by ER-resident (27)
and cytosolic aminopeptidases (28).
Biochemical studies on the specificity of the proteasome revealed three
distinct proteolytic components, which are involved in chymotryptic,
tryptic, and peptidylglutamylpeptide hydrolyzing activities,
respectively. Analysis of the contribution of the individual
This study represents the first detailed characterization of the
proteolytic specificity of the 26 S proteasome. Our data demonstrate
that 26 S and 20 S proteasomes cleave Purification of 26 S Proteasome
All steps were carried out at 4 °C. Approximately 250 ml of
human red blood cells (erythrocyte concentrate, Bloodbank
Universitätsklinikum Tübingen, Tübingen, Germany)
were washed three times with phosphate-buffered saline, pH 7.2, lysed
for 30 min in 1.6× starting volume of buffer A (30 mM
Tris-HCl, pH 7.6, 1.6 mM dithiothreitol (Sigma-Aldrich), 3.25 mM ATP (Sigma-Aldrich), 5 mM
MgCl2). Debris was spun down for 30 min at 10,000 × g (Sorvall RC-5C Plus, GS-3), and the supernatant was
adsorbed to 75 g DEAE-52-Servacel (Serva, Heidelberg, Germany). The batch material was washed three times with 500 ml of buffer B (10 mM Tris-HCl, pH 7.6, 10 mM NaCl, 1.1 mM MgCl2, 0.1 mM EDTA, 1 mM dithiothreitol, 1 mM ATP, 10% (v/v)
glycerol), 125 mM KCl. Bound material was eluted with
buffer B, 250 mM KCl in a total volume of 600 ml (Fig.
2A). Eluted material containing the 26 S proteasome was
precipitated with 40% ammonium sulfate and collected by centrifugation
(22,000 × g, 30 min, Sorvall RC-5C plus, SS-34) The
pellet was resuspended in 10 ml of buffer B, 125 mM KCl,
cleared by centrifugation and subjected to FPLC size exclusion
chromatography (350 ml of HiPrep Sephacryl S-400 in a XK26/70 column)
(Amersham Pharmacia Biotech) and eluted under isocratic conditions
(buffer B, 125 mM KCl). Peak fractions displaying
half-maximal proteolytic activity against the fluorogenic peptide
substrates
succinyl-leucyl-leucyl-valyl-tyrosyl-7-amino-4-methylcoumarin (suc-LLVY-AMC)(Bachem,Heidelberg, Germany) were collected (Fig. 2D) and the ionic strength slowly adjusted to 75 mM KCl with buffer B. The pooled peak fractions were
subjected to FPLC anion exchange chromatography with 75 ml of
TSK-DEAE-650S Toyopearl resin (Tosohaas GmbH, Stuttgart, Germany) in a
XK16/40 column (Amersham Pharmacia Biotech). Bound material was eluted
with a gradient ranging from buffer B, 75 mM KCl, to buffer
B, 500 mM KCl. The proteolytic activity corresponding to
the 26 S proteasome eluted in a single peak around 195 mM
KCl (Fig. 2B). Material displaying at least half-maximal
proteolytic activity was slowly adjusted to 75 mM KCl with
buffer B and subsequently loaded onto 8 ml of arginine-Sepharose-4B resin in a XK16/20 column (Amersham Pharmacia Biotech). Bound proteasome was eluted with a gradient ranging from buffer B, 75 mM KCl to buffer B, 300 mM KCl (Fig.
2E). The 26 S proteasome peak fraction eluted around 169 mM KCl and was collected and concentrated (BioMax 50-kDa
ultrafiltration device, Millipore). Concentrated material was loaded on
a 10-40% glycerol gradient (300 µl of concentrated material/12 ml
in polyallomer tubes (14 mm × 95 mm); Beckman-Coulter, Munich,
Germany). After centrifugation at 100,000 × g for
18 h (Beckman ultracentrifuge Optima L-80, SW40Ti),
fractions of 500 µl were collected and assayed for proteolytic
activity as described above (Fig. 2F). The recovered 26 S
proteasome was stored at 4 °C. Both 26 S proteasome from glycerol
density gradient centrifugation as well as concentrated material from
the arginine-Sepharose-4B eluate were used in this study.
Purification of 20 S Proteasome
Human 20 S proteasome was purified from material eluting at 250 mM KCl (buffer B) of the crude extract adsorbed by
DEAE-52-Servacel (see above). The eluent was chromatographed over gel
filtration and anion exchange columns without prior ammonium sulfate
precipitation (Fig. 2C). Subsequently, 20 S proteasome was
further purified by chromatography with hydroxyapatite, mono Q, and
phenyl-Superose columns as described (32).
Measurement of Proteolytic Activities against Peptide Substrates
with Fluorogenic Leaving Groups
The fluorogenic peptide substrates suc-LLVY-AMC and
H-alanyl-alanyl-phenylalanyl-7-amino-4-methylcoumarin (H-AAF-AMC) were prepared from 10 mM stock solutions in Me2SO
and used in a final concentration of 100 µM. 50 µl of
sample were incubated with 150 µl of buffer C (30 mM
Tris-HCl, pH 7.6, 5 mM MgCl2, 1 mM
ATP, 0.5 mM dithiothreitol, 10 mM KCl)
including the fluorogenic substrate in Ultra-Low 96-well plates
(Corning Costar Europe, Badhoevedorp, The Netherlands). Fluorescence of
the released AMC was determined after 1 h incubation at 37 °C
with a Tecan spectrophotometer (Tecan, Crailsheim, Germany) at 360 nm
excitation and 430 nm emission. Fluorescence readings of released AMC
were recorded as arbitrary (fluorescence) units.
Protease Inhibitors
Lactacystin was purchased from E. J. Corey (Harvard
University, Cambridge, MA), and
H-alanyl-alanyl-phenylalanyl-chloromethylketone (H-AAF-CMK) was from
Sigma-Aldrich. Both inhibitors were used at final concentrations of 50 µM.
Protein Concentration
The amount of protein in pooled fractions and the final
concentrate was determined by a variation of the Lowry method (Bio-Rad DC Protein Assay, Bio-Rad) and bovine serum albumin as a standard. Absorption was measured at 650 nm with a spectrophotometer (Ultrospec 3000, Amersham Pharmacia Biotech).
Denaturing PAGE
5 µg of purified proteasome polypeptides were resolved by 10%
SDS-polyacrylamide gel electrophoresis (PAGE) by standard techniques (33) and transferred to polyvinylidene difluoride (DuPont) or nitrocellulose (Sartorius AG, Göttingen, Germany) with a semidry transfer system (CTI).
Immunoblotting
Detection of human Nondenaturing PAGE
Protein samples (5 µg/lane) were resolved by nondenaturing
PAGE essentially as described by Glickman et al. (13).
Nondenaturing minigels were let run at 150 V for 2 h at 4 °C.
Protein complexes displaying proteolytic activity were visualized by
incubation of the gels for 10 min at 37 °C with suc-LLVY-AMC or
H-AAF-AMC and subsequent exposure to UV light (360 nm). Following the
fluorescence overlay assay, nondenaturing PAGE gels were stained with
Coomassie Brilliant Blue.
In Vitro Degradation of For degradation of The influence of ATP on Separation and Analysis of Cleavage Products
Peptide fragments resulting from in vitro degradation
of Statistical Analysis
Computations were performed using Maple V Release 4 (Waterloo
Maple, Inc.).
Frequencies of Individual Amino Acids at Certain Positions
Relative to Cleavage Sites--
The probability
q(k) for finding a given amino acid exactly
k times in a given position by random selection of cleavage
sites (considering that each single peptide bond can be randomly
selected only once for each enolase molecule) can be calculated
according to the hypergeometric distribution below.
q(k) values were used to calculate two-sided tail
probabilities p to indicate deviation of observed
frequencies from a random selection of certain amino acids at a given
position. Because we considered positions P6 to P6' surrounding a
cleavage site, the total number of potential cleavage sites
(N) in Comparison of Amino Acid Characteristics--
To compare the
characteristics of amino acids at certain positions for significant
differences, the two-sided Student's t test for two
independent data sets was performed. Hydropathicity parameters were
taken from Kyte and Doolittle (35), Bulkiness parameters from Zimmerman
et al. (36), and normalized frequency parameters for
Purification and Assessment of Purity--
Human 26 S proteasome
was enriched from erythrocytes to a >95% degree of purity with
respect to unspecific background protein content of the sample (Fig.
1, A and B). The 20 S and 26 S proteasomes from erythrocytes do not have divergent subunit
composition with respect to the interferon Analysis of Degradation Products--
The primary analysis by
reversed phase HPLC and SDS-PAGE of degradation products from
Comparison of 26 S and 20 S Proteasome Specificity--
The 26 S
proteasome produces fragments with an average length of 10.1 amino acid
residues, as judged from the number and individual length of the
peptides. If the molar amount of fragments is taken into account, the
average peptide length shrinks to 7.2 amino acid residues. In
comparison, the 20 S proteasome generated peptides with average sizes
of 18.3 and 15.8 amino acid residues, respectively. Only fragments that
did not contain the original C or N terminus of the substrate were
computed for the calculations, to avoid any bias on the outcome of size
distribution patterns from fragments derived from cleavages of one
peptide bond only. Fragments with less than 5 amino acids are difficult
to detect and, if present in the digests, do not contribute to the
analysis. Further statistical analysis revealed both divergent features
and qualities common to the 20 S and 26 S proteasomes. The analysis of
the cleavage sites and the hypergeometric (Student's t
test) distribution is summarized in Table
II. The most prominent features of human
26 S and 20 S proteasomes include a preference for hydrophobic amino acids (parameters: Kyte-Doolittle) and especially leucine in P1, so
that fragments arising from the proteasome have a hydrophobic rather
than a charged C terminus. The 20 S cleaves after 11 of the 22 available leucine residues, the 26 S cleaves after 14 of the 22. Turn-promoting (parameters: Levitt) and flexibility-providing amino
acids are not favored (26 S) or even strongly disfavored in P1 (20 S).
Turn-promoting and flexibility-providing amino acid residues are very
rarely found in P2 for both 20 S and 26 S, but the 26 S favors
cleavages if turn-promoting amino acids or especially proline are
available in P1'. Other amino acids enhance (proline in P4) or reduce
(glutamine in P6') the probability of peptide bond hydrolysis by the 26 S. Those preferences did not seem to be significant for the human 20 S. Analogous data from the degradation of In this study we compared the in vitro enzymatic
specificities of 26 S and 20 S proteasomes from human erythrocytes.
Previous investigations (2) have concluded that the 20 S proteasome generates short peptides that can bind to MHC class I molecules following translocation by the transporter associated with antigen processing into the ER. In rare cases, the primary products released by
the 20 S proteasome into the cytosol already carry the correct C and N
termini essential for proper binding to
The participation of proteasomes in antigen presentation is well
established, the relative contribution of 20 S and 26 S subtypes is not
so clear. Targeting of peptides from minigenes as well as whole
proteins to the 26 S proteasome by covalent linkage to ubiquitin leads
to epitope generation and enhanced MHC class I restricted CTL
recognition (16, 18-20, 26, 45). Evidence for the indispensable role
of ubiquitin is contradictory and will have to be analyzed in more
detail (21, 46).
Some proteins can be degraded by the 26 S proteasome without prior
attachment to mono- or polyubiquitin via the For this reason we have now accomplished an in-depth analysis of
degradation products from It has previously been reported that the 20 S proteasomes from yeast
(wild-type and mutant) and from human source do not cleave at random,
but in a highly specific manner (29,
30),2 which is
subunit-dependent for trypsin- and PGPH-like cleavages and
partially subunit-independent for chymotrypsin-like cleavages. A
dominant feature of these studies was the preference for proline in
position 4 (P4) and leucine in P1 upstream from the cleavage site in
digests of yeast enolase 1 with wild-type yeast 20 S proteasome. A
preference for We found that the human 26 S proteasome uses the same parameters for
the destruction of We thank Prof. Dr. Northoff from the blood
bank of the University Hospital Tübingen for the donation of
erythrocyte concentrate samples and Lynne Yakes for editing the
manuscript. We also thank Tobias P. Dick and Klaus Dietz for their
successful efforts to create a statistical evaluation program to serve
our purposes.
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed. Tel.:
49-7071-2980992; Fax: 49-7071-295653; E-mail:
hansjoerg.schild@uni-tuebingen.de.
Published, JBC Papers in Press, May 2, 2000, DOI 10.1074/jbc.M000740200
2
A. K. Nussbaum, manuscript in preparation.
The abbreviations used are:
CTL, cytotoxic T
lymphocyte;
MHC, major histocompatibility complex;
ER, endoplasmic
reticulum;
RP, regulatory particle;
ND, nondenaturing;
PAGE, polyacrylamide gel electrophoresis;
TPP2, tripeptidylpeptidase 2;
HPLC, high pressure liquid chromatography;
FPLC, fast protein liquid
chromatography;
H-AAF-CMK, H-alanyl-alanyl-phenylalanyl-chloromethylketone;
H-AAF-AMC, H-alanyl-alanyl-phenylalanyl-7-amino-4-methylcoumarin;
suc-LLVY-AMC, succinyl-leucyl-leucyl-valyl-tyrosyl-7-amino-4-methylcoumarin;
AMC, 7-amino-4-methylcoumarin.
The Human 26 S and 20 S Proteasomes Generate Overlapping but
Different Sets of Peptide Fragments from a Model Protein
Substrate*
,
,
,
,
§,
, and
¶
Department of Immunology, Institute for Cell
Biology, University of Tübingen, Auf der Morgenstelle 15, D-72076 Tübingen, Germany and the § Department of
Immunohematology and Bloodbank, Leiden University Medical Centre,
Albinusdreef 2, P.O. Box 9600, RC 2300 Leiden, The Netherlands
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-casein with both the 26 S and 20 S proteasome. The data
we obtained show that 26 S and 20 S proteasomes generate overlapping,
but at the same time substantially different, sets of fragments by
following very similar instructions.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2-microglobulin on the lumenal side of the ER. After
release of chaperones and the binding of a suitable peptide to the
binding groove, the trimeric complex is shuttled to the cell surface
(1-3).
-inducible, catalytically active
-subunits LMP2 and LMP7 (10), verified the fundamental importance of
the proteasome for antigen processing.
-subunits, and the inner rings form the central
cavity. They consist of
-subunits harboring the catalytically active
5 (X, LMP7),
1 (Y, LMP2), and
2 (Z, MECL-1) subunits, which
belong to the family of N-terminal nucleophile hydrolases (11, 12).
Substrates probably enter the channel leading to the interior chamber
through a narrow constriction in the central portion of the
-ring,
which is governed by the N-terminal extensions of the
-subunits. In
the absence of SDS, access is restricted to unfolded proteins and short
peptides. It has been suggested that this channel gating effect can be
overcome by regulatory proteins in vivo and in
vitro, e.g. by association of the 20 S proteasome with
the 19 S cap regulatory particle (RP) (13).
-subunits with yeast mutants has demonstrated a clear correlation
between the individual subunits and the cleavage after preferred amino
acids (29). Furthermore, the analysis of the degradation of the entire
protein yeast enolase 1 with yeast 20 S proteasome revealed a
processive mechanism of degradation that yielded peptide fragments with
an average length of 7-8 amino acids. The digestion of enolase 1 generated diverse fragments that enabled a detailed analysis of the
influence of flanking sequences surrounding the cleavage sites. This
revealed the significance of the primary sequence composition next to
the site of peptide bond hydrolysis (30). The influence of proline in
position 4 (P4) upstream from the cleavage site seems to be
particularly important. In contrast, only limited data are
available for assessing the contribution of the 26 S proteasome to
hydrolytic destruction of peptides and entire proteins (24, 31) with
regard to the nature of degradation products.
-casein in such a way that
peptide diversity by differential cleavage site usage is guaranteed,
whereby fragments with hydrophobic amino acids, especially leucine, at
the C terminus, are preferred in both cases. 26 S and 20 S proteasome
appear to operate on the basis of a conserved, underlying matrix for
specificity that is distinct from random cleavage of the substrate
proteins and is not only common to both conformations from human
source, but to the 20 S proteasome from bakers' yeast, too. The
mapping of
-casein fragments provides the basis for more detailed
knowledge of the integration of the 26 S proteasome into the
protein-degrading and antigen-supplying machinery of the cytosol.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2 and human LMP-7 was
performed with mouse monoclonal antibody MCP-21 (34)
anti-
2 and rabbit polyclonal antiserum anti-LMP-7
(PW8200, Affiniti Research Products Ltd., Mamhead, United Kingdom).
-Casein
-casein, 10 µg of proteasome were
incubated for 3, 6, and 18 h at 37 °C with 100 µg of
-casein in buffer C in a final volume of 0.5 ml. Data are from
incubations with a molar ratio of 1:300 to 1:800 (20 S or 26 S
proteasome:
-casein), depending on the relative amounts of CP,
RP1CP, and RP2CP. Digests were stopped by
freezing the samples at
80 °C.
-casein degradation by the 20 S proteasome
was tested with 25 µg of 20 S proteasome and 100 µg of
-casein
in buffer C with or without ATP (1 mM). Reactions were stopped after 3 and 6 h.
-casein were separated by reversed phase HPLC (SMART system,
Amersham Pharmacia Biotech) over a µRP C2/C18 SC2.1/10 column. Eluent
A consisted of 0.1% trifluoroacetic acid; eluent B consisted of 0.081% trifluoroacetic acid, 80% acetonitrile. The gradient was 0-70% eluent B in 62.5 min with a flow rate of 150 µl/min.
Fractions were collected by peak fractionation with a maximal volume of 500 µl. Peak fractions were dried and redissolved in 40% methanol, 1% formic acid and subsequently analyzed by matrix-assisted laser desorption ionization/time of flight mass spectrometry (G2025A, Hewlett
Packard, Waldbronn, Germany) and automated Edman N-terminal sequencing
(Procise 494A pulsed liquid protein sequencer; Applied Biosystems,
Weiterstadt, Germany)
n is the number of observed cleavages under
consideration, N is the total number of potential cleavages
in
(Eq. 1)
-casein, k is the observed frequency of a given amino
acid in a given position relative to the cleavage site, and
K is the total number of a given amino acid in
-casein.
-casein was reduced from 209 to 199.
-turn from Levitt (37). Results are shown as p values and
mean value differences including the 95% confidence limit. Only
differences with p values <0.05 are reported.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-inducible subunits. In
contrast to the 20 S immunoproteasome isolated from interferon
-induced cells, neither 20 S nor 26 S show incorporation of LMP-7,
which is crucial for the the formation of immunoproteasomes (34) (Fig.
1C). The process of purification (Fig.
2) was based on the recovery of fractions
displaying proteolytic activity toward the chymotryptic substrate
suc-LLVY-AMC. The increase in specific activity is at least 5,000-fold,
not taking into account the fact that a substantial amount of measured
activity at early points in the purification procedure can be
attributed to 20 S proteasomes (Table I).
In fluorescence overlay assays, the glycerol density gradient-purified 26 S fraction displays only minimal background activity against the
fluorogenic substrate H-AAF-AMC. This is the preferred substrate among
a large variety of short fluorogenic model peptides for tripeptidylpeptidase 2 (TPP2), a high molecular weight amino- and
endopeptidase from the cytosol (39). The serine protease TPP2 has been
associated with the processing pathway for MHC class I peptide ligands,
where it could serve as a cytosolic trimming peptidase (39). To
elucidate the influence of TPP2, which coelutes with the 26 S, but not
the 20 S proteasome from size exclusion as well as anion exchange
chromatography columns on substrate degradation in vitro, we
performed ND-PAGE analysis together with fluorescent substrate overlay
of samples from purified 20 S and 26 S proteasomes. In addition, we
looked at intermediate products of purification. These and purified
proteasomes were preincubated with the proteasome inhibitor lactacystin
or the serine protease inhibitor H-AAF-CMK. The concentrated 26 S
proteasome-containing fraction from the arginine-Sepharose-4B
chromatography step displays a distinct proteolytic complex that
migrates even slower than the 26 S proteasome complex with two
regulatory caps (RP2CP). It also reveals a more improved
activity against the fluorogenic substrate H-AAF-AMC than the 26 S
proteasome (Fig. 3), which can be
completely abolished by preincubation of the sample with H-AAF-CMK. The
weak activity of the 26 S proteasome complexes toward H-AAF-AMC, on the
other hand, does not change upon treatment with H-AAF-CMK (Fig. 3). The
glycerol density gradient-purified 26 S proteasome (Figs. 1
(A and B) and 4 (A-D)) shows very weak activity toward H-AAF-AMC (Fig. 4,
A and C) and only trace amounts of H-AAF-CMK inhibitable activity, which, surprisingly, migrated faster than the 26 S complexes (Fig. 4A). In comparison, the 20 S proteasome was free of any contaminants and showed high activity toward H-AAF-AMC in the presence or absence of H-AAF-CMK (Fig. 4A). Both 20 S
and 26 S proteasomes displayed complete inhibition of H-AAF-AMC
degradation following preincubation with lactacystin (Fig.
4C). The same analysis of purified proteasomes by the
fluorescence overlay assay was conducted in the presence of the
reference fluorogenic substrate for the chymotryptic activity of the
proteasome, suc-LLVY-AMC. The preincubation of 20 S and 26 S proteasome
with H-AAF-CMK did not yield any reduction of sample activity (Fig.
4B), whereas lactacystin inhibited the degradation of
suc-LLVY-AMC (Fig. 4D). The results allow us to conclude
that our 20 S and 26 S proteasome preparations were of high purity and
suitable for the in vitro degradation of peptides and
proteins. However, to eliminate the possibility that trace amounts of
TPP2 contribute to peptide generation, all in vitro digests
were performed in the presence or absence of the TPP2 inhibitor
H-AAF-CMK. 26 S proteasomes remained stable for more than 18 h at
37 °C, as judged from fluorescence overlay of ND-PAGE gels (Fig.
3B) and Coomassie staining of ND-PAGE gels (data not shown).
No active 20 S proteasome could be detected in 26 S fractions after
incubation at 37 °C for up to 48 h (data not shown), excluding
a contribution of 20 S proteasomes to the fragments generated by 26 S
proteasomes.

View larger version (51K):
[in a new window]
Fig. 1.
A, fluorescence overlay assay with
suc-LLVY-AMC of ND-PAGE with purified human 20 S and 26 S proteasome.
The 26 S preparation contains core particle (CP) associated
with one (RP1CP) or two
(RP2CP) regulatory particles (RP).
B, Coomassie Blue staining of ND-PAGE reveals no other
protein besides the bands assigned to 20 S and 26 S proteasome in the
respective purification products. C, immunoblotting of
proteasome subunits. 26 S and 20 S proteasome from erythrocytes and
immunoproteasome express equal amounts of the constitutive
-subunit
2. Only the immunoproteasome (20S-i) shows
expression of the interferon-
-inducible subunit LMP-7.

View larger version (43K):
[in a new window]
Fig. 2.
Method of purification. A,
batch adsorption. The major proteolytic peak elutes at 250 mM to 300 mM KCl in buffer B. The eluate was
diluted and loaded onto the anion exchange column directly
(C), or following prior ammonium sulfate precipitation of
the 26 S proteasome containing fraction (B). The 26 S
proteasome elutes with a maximum at 195 mM KCl in buffer B,
the 20 S proteasome with a maximum at 137 mM KCl,
respectively. D, size exclusion chromatography of the 26 S-containing fraction shown in B. E, affinity
chromatography of the 26 S-containing peak fraction shown in
D. The 26 S-containing fraction elutes with a maximum at 169 mM KCl in buffer B. F, final purification of 26 S proteasome from the peak fraction shown in E by density
gradient centrifugation.
Purification

View larger version (52K):
[in a new window]
Fig. 3.
A, fluorescence overlay assay with
H-AAF-AMC of ND-PAGE with a 26 S proteasome containing purification
intermediate (peak fraction from affinity chromatography). TPP2
coelutes with the 26 S proteasome (lane 1), and
the proteolytic degradation of H-AAF-AMC mediated through TPP2 can be
inhibited by preincubation of the sample with H-AAF-CMK
(lane 3). Lane 2 is empty.
B, fluorescence overlay of 26 S proteasome incubated at
37 °C for up to 48 h. Control, 0.02% SDS. SDS
completely abolishes the activity of the 26 S proteasome.

View larger version (54K):
[in a new window]
Fig. 4.
Fluorescence overlay assay with suc-LLVY-AMC
and H-AAF-AMC in the presence and absence of lactacystin or H-AAF-CMK
of ND-PAGE with purified human 20 S and 26 S proteasome. 26 S and
20 S hydrolyze H-AAF-AMC and are insensitive to H-AAF-CMK. A faint,
H-AAF-CMK-inhibitable background fluorescence in the 26 S fraction
suggests low amounts of serine protease activity (A). The
hydrolysis of H-AAF-AMC mediated by 20 S or 26 S, as well as the
background fluorescence in the 26 S fraction, is inhibited by
lactacystin (C). The hydrolytic activity of 20 S and 26 S
toward suc-LLVY-AMC is not inhibited by H-AAF-CMK (B), but
to full extent by lactacystin (D). 20 S hydrolyses the two
different substrates equally well, 26 S displays much higher activity
toward suc-LLVY-AMC, than toward H-AAF-AMC (A and
B).
-casein generated in incubations for up to 6 h revealed no
detectable difference for peptide products, whether H-AAF-CMK had been
added or not (Fig. 5). In contrast,
-casein digests using 20 S or 26 S proteasomes resulted in clearly divergent product patterns (Fig. 5, Aand B). To
exclude an influence of ATP on the 20 S proteasome and on the
substrate, control digests in the presence and absence of ATP were
included (Fig. 5, C and D), resulting in
identical patterns of peptide peaks. Therefore, ATP has no effect on
the degradation of
-casein by 20 S proteasomes. To allow for an
accurate assessment of the differences in the enzymatic activity of
those closely related proteolytic complexes, peak fractions from
digests up to 6 h were subjected to mass spectrometric analysis
(matrix-assisted laser desorption ionization/time of flight) and
quantitative Edman degradation. 74 different fragments for the 20 S and
66 for the 26 S proteasome were characterized. The fragments and their
C and N termini are projected onto the map that represents the entire
amino acid sequence of
-casein (Fig.
6). Different fragments from the same
digest were detected in varying amounts, ranging from less than 1 pmol
to 170 pmol (from an input of 4 nmol). As previously observed in
digests of enolase-1 by yeast 20 S proteasome (30), overlapping
fragments are generated, indicating the alternating use of certain
cleavage sites. Taken together, these fragments fit into a pattern that gives the first clue for the assessment of proteasomal activity and
specific differences in enzymatic activity.

View larger version (36K):
[in a new window]
Fig. 5.
Optical density at 214 nm of eluted digestion
products from reversed phase HPLC. Black
line,
-casein (control); light gray
line, 20 S proteasome +
-casein; dark
gray line, 26 S proteasome +
-casein.
A and B, after 6 h. Digest in A
had been preincubated for 1 h with 100 µM H-AAF-CMK
before adding
-casein. C, 20 S proteasome +
-casein, 1 mM ATP added. D, 20 S proteasome +
-casein,
no ATP added.

View larger version (27K):
[in a new window]
Fig. 6.
Fragments detected from digestion of
-casein by 26 S and 20 S proteasome after 6 h. Map in A shows a projection of all fragments
generated by the 20 S proteasome onto the
-casein sequence. Map in
B shows a projection of of all fragments generated by the 26 S proteasome onto the
-casein sequence.
-casein by wildtype yeast 20 S proteasome show preferences for hydrophobic and bulky amino acids in
P1, proline, and other turn-promoting and flexibility-providing amino
acids in P4. Amino acids that are significantly reduced are proline in
P2' and flexibility-providing and turn-promoting residues in P1. The
analysis of the cleavages made by both human 20 S and 26 S proteasomes
underlines the importance of leucine in P1. Extension of this form of
analysis to human 20 S and 26 S and yeast 20 S highlights the
importance of leucine in P1 and proline in P4 and P1'. These
preferences in specificity are virtually conserved between different
proteasomal conformations from human source and the 20 S
proteasome from S. cerevisiae.
Cleavage preferences of the proteasome in bovine
-casein
-casein by wild type 20 S proteasome from
Saccharomyces cerevisiae (see Footnote 2). Line 2, analysis
of cleavages obtained from digests of
-casein by 20 S proteasome
from human source. Line 3, analysis of cleavages obtained from digests
of
-casein by 26 S proteasome from human source.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2-microglobulin/heavy chain dimers (40), whereas other
fragments that arise from the central chamber of the
self-compartmentalizing multicatalytic core particle function as
precursors (8). The precursors are derived from a proteolytic event
that in many cases yields the C terminus that fits without further
processing into the binding pocket of an empty MHC class I molecule.
The N terminus in contrast has to be generated by a different process.
Putative ligands with N-terminal elongations are subjected to a process
that has been termed trimming (41) by endo- and aminopeptidases in
independent or concerted reactions, and evidence has been obtained that
such trimming can occur in the cytosol and inside the lumen of the ER
(42). Suggested candidates are leucine aminopeptidase (5) and
tripeptidylpeptidase 2 (TPP2) (39) in the cytosol and a group of
ER-resident stress proteins that can associate with MHC class I binding
peptides (43, 44).
- or
-amino groups
of the substrate. This has been shown for c-Jun (47), ornithine
decarboxylase (23, 24, 48), ornithine decarboxylase containing a short
stretch from ovalbumin (26), denatured insulin-like growth factor,
lactalbumin, and
-casein as well as fluorescein isothiocyanate-labeled casein (31). The degradation of c-Fos seems to
be partially ubiquitin-independent (49) and
ubiquitin-dependent (50). Whether 20 S and 26 S proteasomes
contribute independently to the generation of MHC class I ligands or
together is not known. Studies addressing the specificities of 20 S
proteasomes alone will therefore be of limited in vivo
relevance if 20 S and 26 S proteasomes differ in their cleavage site selection.
-casein. This protein was incubated with
both 26 S and 20 S proteasomes for up to 6 h (Fig. 5). The recovered fragments were separated on reversed phase HPLC columns, and
the elution profiles gave the first indication of a substantial difference in the nature of products (Fig. 5), as previously reported (31). Identification of fragments revealed that the 26 S proteasome generated shorter cleavage products, when compared with peptides derived from 20 S proteasome-mediated degradation (Fig.
7). This finding contradicts the
assumption that the 26 S proteasome might be responsible for the
initial destruction of ubiquitin-tagged protein substrates, followed by
additional 20 S proteasome-mediated cleavages. Instead, our results
suggest that the action of 20 S and 26 S proteasomes is carried out
independently. However, we cannot rule out the possibility that the 20 S proteasome produces a higher number of fragments than the 26 S
proteasome with less than 5 amino acids that escape detection.

View larger version (21K):
[in a new window]
Fig. 7.
Fragment length distribution. n,
number of fragments. M, average fragment length.
A and C, frequencies of different fragments with
the same size obtained from 26 S (A) and 20 S proteasome
(C) digests. B and D, frequencies
(pmol) of fragments with the same size.
-turn-promoting amino acids in P1' was observed, too.
An effect of proline on the generation of two CTL epitopes from c-akt
and pp89 from synthetic precursor peptides in vitro was
demonstrated by Shimbara et al. (38) for 20 S the proteasome with or without the PA28 activator. Shimbara and co-workers suggested a
proline-dependent escape from random cleavage by the proteasome.
-casein (proline in P4, leucine in P1,
-turn-promoting amino acids in P1'; see Table II), although the
criteria, despite their statistical significance, are less stringent
than for the yeast 20 S proteasome. Additional features of the human 26 S point toward a preference for amino acids other than
-turn-promoting ones in P2 and glutamine in P6'. Intriguingly, the
human 20 S proteasome did not show the proline effect for P4, but
shared other features with the 26 S proteasome, especially a strong
preference for leucine in P1 and a reduction of
-turn-promoting amino acids in P2. A comparison with preliminary data from the cleavage
of
-casein by the yeast 20 S proteasome2 confirmed the
significance of the observed enrichments for proline in P4 and amino
acids with hydrophobic properties in P1. In summary, these data
demonstrate that the different conformations of the proteasome employ
common and conserved parameters to yield peptide fragment sets that are
only about 25% identical. Despite this small proportion, approximately
50% of the cleavage sites found were virtually identical. Thus, the 26 S and 20 S proteasomes together generate a diverse pool of peptides
with hydrophobic C termini that could be eligible for binding to MHC
class I heterodimers. This diversity cannot be caused by a different
contribution of interferon
-inducible
-subunits because 20 S and
26 S proteasomes from erythrocytes lack LMP7, which is required for the
maturation of immunoproteasomes (38). We speculate that the 19 S
regulatory particle brings about a conformational change in the
quaternary structure of the core particle that induces a change in
specificity. Nevertheless, we cannot exclude the possibility that an
undetectable imbalance in active
-subunit composition or
modification between the 26 S and 20 S proteasomes is the cause of the
specificity differences observed. Future studies will have to determine
whether or not polyubiquitinated proteins are degraded by the
employment of similar cleavage specificities in comparison to peptides
and proteins without such a targeting tag. Finally, the manifestation of common rules for proteasomal degradation, regardless of the substrate, will hopefully improve the epitope prediction from artificial and endogenous peptide and protein substrates in its relevance to human disease.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Rammensee, H. G.,
Bachmann, J.,
and Stevanovic, S.
(1999)
MHC Ligands and Peptide Motifs
, Landes Bioscience, Austin, TX
2.
Rock, K. L.,
and Goldberg, A. L.
(1999)
Annu. Rev. Immunol.
17,
739-779
3.
Pamer, E.,
and Cresswell, P.
(1998)
Annu. Rev. Immunol.
16,
323-358
4.
Rock, K. L.,
Gramm, C.,
Rothstein, L.,
Clark, K.,
Stein, R.,
Dick, L.,
Hwang, D.,
and Goldberg, A. L.
(1994)
Cell
78,
761-771
5.
Craiu, A.,
Akopian, T.,
Goldberg, A.,
and Rock, K. L.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
10850-10855
6.
Stoltze, L.,
Dick, T. P.,
Deeg, M.,
Pommerl, B.,
Rammensee, H. G.,
and Schild, H.
(1998)
Eur. J. Immunol.
28,
4029-4036
7.
Niedermann, G.,
Butz, S.,
Ihlenfeldt, H. G.,
Grimm, R.,
Lucchiari, M.,
Hoschutzky, H.,
Jung, G.,
Maier, B.,
and Eichmann, K.
(1995)
Immunity
2,
289-299
8.
Dick, T. P.,
Ruppert, T.,
Groettrup, M.,
Kloetzel, P. M.,
Kuehn, L.,
Koszinowski, U. H.,
Stevanovic, S.,
Schild, H.,
and Rammensee, H. G.
(1996)
Cell
86,
253-262
9.
Groettrup, M.,
Soza, A.,
Eggers, M.,
Kuehn, L.,
Dick, T. P.,
Schild, H.,
Rammensee, H. G.,
Koszinowski, U. H.,
and Kloetzel, P. M.
(1996)
Nature
381,
166-168
10.
Fehling, H. J.,
Swat, W.,
Laplace, C.,
Kuhn, R.,
Rajewsky, K.,
Muller, U.,
and von Boehmer, H.
(1994)
Science
265,
1234-1237
11.
Groll, M.,
Ditzel, L.,
Löwe, J.,
Stock, D.,
Bochtler, M.,
Bartunik, H. D.,
and Huber, R.
(1997)
Nature
386,
463-471
12.
Baumeister, W.,
Walz, J.,
Zuhl, F.,
and Seemuller, E.
(1998)
Cell
92,
367-380
13.
Glickman, M. H.,
Rubin, D. M.,
Fried, V. A.,
and Finley, D.
(1998)
Mol. Cell. Biol.
18,
3149-3162
14.
Coux, O.,
Tanaka, K.,
and Goldberg, A. L.
(1996)
Annu. Rev. Biochem.
65,
801-847
15.
Glickman, M. H.,
Rubin, D. M.,
Coux, O.,
Wefes, I.,
Pfeifer, G.,
Cjeka, Z.,
Baumeister, W.,
Fried, V. A.,
and Finley, D.
(1998)
Cell
94,
615-623
16.
Townsend, A.,
Bastin, J.,
Gould, K.,
Brownlee, G.,
Andrew, M.,
Coupar, B.,
Boyle, D.,
Chan, S.,
and Smith, G.
(1988)
J. Exp. Med.
168,
1211-1224
17.
Cerundolo, V.,
Benham, A.,
Braud, V.,
Mukherjee, S.,
Gould, K.,
Macino, B.,
Neefjes, J.,
and Townsend, A.
(1997)
Eur. J. Immunol.
27,
336-341
18.
Tobery, T.,
and Siliciano, R. F.
(1999)
J. Immunol.
162,
639-642
19.
Tobery, T. W.,
and Siliciano, R. F.
(1997)
J. Exp. Med.
185,
909-920
20.
Grant, E. P.,
Michalek, M. T.,
Goldberg, A. L.,
and Rock, K. L.
(1995)
J. Immunol.
155,
3750-3758
21.
Michalek, M. T.,
Grant, E. P.,
Gramm, C.,
Goldberg, A. L.,
and Rock, K. L.
(1993)
Nature
363,
552-554
22.
Driscoll, J.,
and Goldberg, A. L.
(1990)
J. Biol. Chem.
265,
4789-4792
23.
Murakami, Y.,
Matsufuji, S.,
Kameji, T.,
Hayashi, S.,
Igarashi, K.,
Tamura, T.,
Tanaka, K.,
and Ichihara, A.
(1992)
Nature
360,
597-599
24.
Tokunaga, F.,
Goto, T.,
Koide, T.,
Murakami, Y.,
Hayashi, S.,
Tamura, T.,
Tanaka, K.,
and Ichihara, A.
(1994)
J. Biol. Chem.
269,
17382-17385
25.
Michalek, M. T.,
Grant, E. P.,
and Rock, K. L.
(1996)
J. Immunol.
157,
617-624
26.
Ben-Shahar, S.,
Komlosh, A.,
Nadav, E.,
Shaked, I.,
Ziv, T.,
Admon, A.,
DeMartino, G. N.,
and Reiss, Y.
(1999)
J. Biol. Chem.
274,
21963-21972
27.
Paz, P.,
Brouwenstijn, N.,
Perry, R.,
and Shastri, N.
(1999)
Immunity
11,
241-251
28.
Anton, L. C.,
Snyder, H. L.,
Bennink, J. R.,
Vinitsky, A.,
Orlowski, M.,
Porgador, A.,
and Yewdell, J. W.
(1998)
J. Immunol.
160,
4859-4868
29.
Dick, T. P.,
Nussbaum, A. K.,
Deeg, M.,
Heinemeyer, W.,
Groll, M.,
Schirle, M.,
Keilholz, W.,
Stevanovic, S.,
Wolf, D. H.,
Huber, R.,
Rammensee, H. G.,
and Schild, H.
(1998)
J. Biol. Chem.
273,
25637-25646
30.
Nussbaum, A. K.,
Dick, T. P.,
Keilholz, W.,
Schirle, M.,
Stevanovic, S.,
Dietz, K.,
Heinemeyer, W.,
Groll, M.,
Wolf, D. H.,
Huber, R.,
Rammensee, H. G.,
and Schild, H.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
12504-12509
31.
Kisselev, A. F.,
Akopian, T. N.,
Woo, K. M.,
and Goldberg, A. L.
(1999)
J. Biol. Chem.
274,
3363-3371
32.
Kuehn, L.,
Dahlmann, B.,
Gauthier, F.,
and Neubauer, H. P.
(1989)
Biochim. Biophys. Acta
991,
263-271
33.
Laemmli, U. K.
(1970)
Nature
227,
680-685
34.
Grusby, M. J.,
Johnson, R. S.,
Papaioannou, V. E.,
and Glimcher, L. H.
(1991)
Science
253,
1417-1420
35.
Kyte, J.,
and Doolittle, R. F.
(1982)
J. Mol. Biol.
157,
105-132
36.
Zimmerman, J. M.,
Eliezer, N.,
and Simha, R.
(1968)
J. Theor. Biol.
21,
170-201
37.
Levitt, M.
(1978)
Biochemistry
17,
4277-4285
38.
Shimbara, N.,
Ogawa, K.,
Hidaka, Y.,
Nakajima, H.,
Yamasaki, N.,
Niwa, S.,
Tanahashi, N.,
and Tanaka, K.
(1998)
J. Biol. Chem.
273,
23062-23071
39.
Geier, E.,
Pfeifer, G.,
Wilm, M.,
Lucchiari-Hartz, M.,
Baumeister, W.,
Eichmann, K.,
and Niedermann, G.
(1999)
Science
283,
978-981
40.
Dick, T. P.,
Stevanovic, S.,
Keilholz, W.,
Ruppert, T.,
Koszinowski, U.,
Schild, H.,
and Rammensee, H. G.
(1998)
Eur. J. Immunol.
28,
2478-2486
41.
Falk, K.,
Rötzschke, O.,
and Rammensee, H. G.
(1990)
Nature
348,
248-251
42.
Elliott, T.,
Willis, A.,
Cerundolo, V.,
and Townsend, A.
(1995)
J. Exp. Med.
181,
1481-1491
43.
Lammert, E.,
Stevanovic, S.,
Brunner, J.,
Rammensee, H. G.,
and Schild, H.
(1997)
Eur. J. Immunol.
27,
1685-1690
44.
Spee, P.,
and Neefjes, J.
(1997)
Eur. J. Immunol.
27,
2441-2449
45.
Ben-Shahar, S.,
Cassouto, B.,
Novak, L.,
Porgador, A.,
and Reiss, Y.
(1997)
J. Biol. Chem.
272,
21060-21066
46.
Cox, J. H.,
Galardy, P.,
Bennink, J. R.,
and Yewdell, J. W.
(1995)
J. Immunol.
154,
511-519
47.
Treier, M.,
Staszewski, L. M.,
and Bohmann, D.
(1994)
Cell
78,
787-798
48.
Murakami, Y.,
Matsufuji, S.,
Tanaka, K.,
Ichihara, A.,
and Hayashi, S.
(1993)
Biochem. J.
295,
305-308
49.
Salvat, C.,
Jariel-Encontre, I.,
Acquaviva, C.,
Omura, S.,
and Piechaczyk, M.
(1998)
Oncogene
17,
327-337
50.
Stancovski, I.,
Gonen, H.,
Orian, A.,
Schwartz, A. L.,
and Ciechanover, A.
(1995)
Mol. Cell. Biol.
15,
7106-7116
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
I. Ginodi, T. Vider-Shalit, L. Tsaban, and Y. Louzoun Precise score for the prediction of peptides cleaved by the proteasome Bioinformatics, February 15, 2008; 24(4): 477 - 483. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. A. York, N. Bhutani, S. Zendzian, A. L. Goldberg, and K. L. Rock Tripeptidyl Peptidase II Is the Major Peptidase Needed to Trim Long Antigenic Precursors, but Is Not Required for Most MHC Class I Antigen Presentation J. Immunol., August 1, 2006; 177(3): 1434 - 1443. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Dakappagari, T. Maruyama, M. Renshaw, P. Tacken, C. Figdor, R. Torensma, M. A. Wild, D. Wu, K. Bowdish, and A. Kretz-Rommel Internalizing Antibodies to the C-Type Lectins, L-SIGN and DC-SIGN, Inhibit Viral Glycoprotein Binding and Deliver Antigen to Human Dendritic Cells for the Induction of T Cell Responses J. Immunol., January 1, 2006; 176(1): 426 - 440. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. Towne, I. A. York, J. Neijssen, M. L. Karow, A. J. Murphy, D. M. Valenzuela, G. D. Yancopoulos, J. J. Neefjes, and K. L. Rock Leucine Aminopeptidase Is Not Essential for Trimming Peptides in the Cytosol or Generating Epitopes for MHC Class I Antigen Presentation J. Immunol., November 15, 2005; 175(10): 6605 - 6614. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Donnes and O. Kohlbacher Integrated modeling of the major events in the MHC class I antigen processing pathway Protein Sci., August 1, 2005; 14(8): 2132 - 2140. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bhasin and G. P. S. Raghava Pcleavage: an SVM based method for prediction of constitutive proteasome and immunoproteasome cleavage sites in antigenic sequences Nucleic Acids Res., July 1, 2005; 33(suppl_2): W202 - W207. [Abstract] [Full Text] [PDF] |